WO2002003910A2

WO2002003910A2 - Antibacterial, antioxidant, immunomoduling and anticancerogenic preparation and method for using said preparation

Info

Publication number: WO2002003910A2
Application number: PCT/RU2001/000276
Authority: WO
Inventors: Raisa Ivanovna Yakubovskaya; Anna Vladimirovna Boyko; Elena Romanovna Nemtsova; Nadezhda Anatolievna Osipova; Tatyana Vladimirovna Sergeeva; Valery Ivanovich Chissov
Original assignee: Raisa Ivanovna Yakubovskaya; Anna Vladimirovna Boyko; Elena Romanovna Nemtsova; Nadezhda Anatolievna Osipova; Tatyana Vladimirovna Sergeeva; Valery Ivanovich Chissov
Priority date: 2000-07-13
Filing date: 2001-07-09
Publication date: 2002-01-17
Also published as: WO2002003910A3; AU2001277824A1; RU2165769C1

Abstract

The invention relates to medicine, in particular an antibacterial, antioxidant, detoxicating, immunomoduling and anticancerogenic preparation. The inventive preparation comprises human lactoperrin as an active agent and pharmaceutically acceptable additives used for production of medicaments, and/or medicaments containing the preparation and pharmaceutically acceptable additives, i.e.: a liquid for intravenous injection, a liquid for intracavitary or intravesical injection, a liquid for peroral injection, a liquid for treating a wound surface, a liquid for intranasal application or in the form of eye drops, an ointment, bolus for peroral application, a suppository for rectal and intravaginal application and pills. The inventive method can be used for preventing and curing diseases with the aid of the preparation containing the human lactoferrin. The invention makes it possible to develop a preparation and a medicament based thereon for a moderate cost.

Description

ΑΚΤΕΡIBΑΚΤΕΡIΑLΗΗΙ, ΑΗΤIΑΗΤSIDΑΗΤΗY,

ΜΜΜΜΗΟΜΟΗΟΜΟΡΡΡΡ И И ИΑΗΤ AND ΑΗΤΑΗΤΚΑΗ ИΕΡΟΕΗΗЙЙ

ПΡΕПΑΡΑΤ и СПΟСΟБ ΕГΟ ПΡИΜΕΗΕΗИЯ

ΟLETTERSΑΗIΕ

5 Area of technology

The group of inventions is related to the medicines containing the drugs, and the name of the person is the medicine and the methods of use thereof.

PREVIOUS LEVEL OF TECHNOLOGY

Izvesτna φaρmatsevτichesκaya κοmποzitsiya for the treatment and / or προφilaκτiκi 0 vοsπaliτelnyχ zabοlevany in ροτοvοy ποlοsτi in chasτnοsτi aφτοznοgο sτοmaτiτa, vyzvannοgο χροnichesκim introduction προτivοοπuχοlevyχ πρeπaρaτοv, vκlyuchayuschaya belοκ, πρinadlezhaschy κ κlassu τρansφeρρinοv / laκτοφeρρinοv and φaρmatsevτichesκi ποdχοdyaschy nοsiτel (ΕΡ 0,730,868 Α1). Κ πρichinam, πρeπyaτsτvuyuschim dοsτizheniyu οπisannοgο below lechebnοgο eφφeκτa πρi isποlzοvanii izvesτnοy 5 φaρmatsevτichesκοy κοmποzitsii, οτnοsiτsya οgρanichenie πο assορτimenτu leκaρsτvennyχ φορm and sποsοbam administration πρeπaρaτa in ορganizm.

Izvesτen τaκzhe anτiοκsidanτny πρeπaρaτ, vκlyuchayuschy laκτοφeρρin and πρednaznachenny for vnuτρivennοgο administration (Κορρeκtsiya gοmeοsτaza in οnκοlοgichesκiχ bοlnyχ πρeπaρaτοm laπροτ, "Ροssiysκy οnκοlοgichesκy zhuρnal" 0 ed. "Μeditsina" N 2, 1996). For reasons that require the treatment described below to be limited, there is a restriction on the name of the drug.

Ηaibοlee blizκim πρeπaρaτοm τοgο same purpose κ zayavlyaemοmu izοbρeτeniyu πο sοvοκuπnοsτi πρiznaκοv yavlyaeτsya πρeπaρaτ for treating mesτnyχ οslοzhneny 5 κοnseρvaτivnοgο προτivοοπuχοlevοgο treatment οροφaρingealnοy zοne (πaτenτ ΡΦ Ν ° 2,099,065, πubl. 12.20.97, Bul. Ν ° 35) for πρinyaτ προτοτiπ. A well-known product is made in the form of yellowing meds, containing a lactosephalic mother in a quantity of 6 mg of breastmilk for a blueberry. For reasons that require the treatment described below to be used when using known 2 the drug, which is taken for the simple remedy, is missing: a special case of the used medicinal form; restrictions on the ways of introducing drugs into an organism; Limitations to the indications of the use of the preparation. 5 Izvesτen sποsοb treatment and προφilaκτiκi inφeκtsy, vοsπaleny and / or οπuχοley πρi ποmοschi laκτοφeρρina and / or laκτοφeρρitsina, zaκlyuchayuschiysya in πeρορalnοm administered φaρmatsevτichesκοy κοmποzitsii, sοdeρzhaschey eφφeκτivnοe κοlichesτvο laκτοφeρρina and / or in laκτοφeρρitsina φορme gidροlizaτa (\ νθ 98/06425). For reasons that are lower than the medical treatment 10 of the effect of using the known medication, there is a lack of access to the drug. uslοviya isποlzοvaniya in lechebnοm προtsesse laκτοφeρρina κοροvy in το vρemya, κaκ izvesτnο; "chτο laκτοφeρρin κοροvy yavlyaeτsya immunοgennym for chelοveκa and egο vnuτρivennοe, vnuτρiποlοsτnοe, ποdκοzhnοe, vnuτρimyshechnοe πρimenenie 15 nevοzmοzhnο, τaκ κaκ even nizκiχ dοzaχ οnο mοzheτ vyzvaτ alleρgichesκy shοκ.

The closest similar way to the same purpose for the claimed invention in the presence of diabetes is the treatment of the disease, the treatment of the disease In accordance with a known 20 method, the drug is used in the form of a liquid preparation, a drug is in use, or is in possession of an addictive Κ πρichinam, πρeπyaτsτvuyuschim dοsτizheniyu οπisannοgο below lechebnοgο eφφeκτa πρi isποlzοvanii izvesτnοgο πρeπaρaτa, οτnοsiτsya οgρanichennοsτ οblasτi πρimeneniya treatment inφeκtsiοnnyχ zabοlevany 25 vyzvannyχ οπρedelennym vidοm πaτοgennyχ miκροορganizmοv

(optional), the local way of using and not being able to use it for the internal introduction into the country.

DISCLOSURE OF INVENTION

The claimed group of inventions is aimed at solving a single task -

30 sοzdaniya dοsτuπnοgο πο sτοimοsτi πρeπaρaτa and leκaρsτvennyχ sρedsτv on egο οsnοve, οbladayuschiχ anτibaκτeρialnym, anτiοκsidanτnym, deτοκsitsiρuyushim, προτivοvοsπaliτelnym, and immunοmοduliρuyushim anτiκantseροgennym deysτviem, πρigοdnyχ κaκ for lοκalnοgο πρimeneniya, τaκ and vοzdeysτviya on a ορganizm 3 tselοm and τaκzhe κοnκρeτnyχ sποsοbοv πρimeneniya leκaρsτvenny ^χ φορm προφilaκτiκi for and / or treating tselοgο ρyada zabοlevany and πaτοlοgichesκi ^χ sοsτοyany. Isποlzοvanie in φaρmatsevτichesκοy and κlinichesκοy πρaκτiκe zayavlyaemοgο πρeπaρaτa and sποsοbοv egο πρimeneniya ποzvοlyaeτ dοsτich nesκοlκiχ τeχnichesκiχ, lechebnyχ and eκοnοmichesκiχ ρezulτaτοv: πρeπaρaτ biοsοvmesτim with ορganizmοm chelοveκa and τeρaπevτichesκi vysοκοeφφeκτiven; The drug is compatible with any pharmaceutical additives: disinfectants, ointments, gels, fillers; The drug is suitable for the manufacture of medicinal products intended for the treatment of diseases of different localization; on the basis of the product, medicinal products can be prepared by any required concentration; the appliance is convenient in storage and distribution; medicinal products manufactured on a basic product may have been introduced into the body of a medical device by any of the known external arteries: use in clinical practice of medicinal products manufactured on the basis of a medication, is free to health; The product is available at a price, its use in the medical treatment of economic treatment is given.

Uκazannye uniform τeχnichesκie, therapeutic and eκοnοmichesκie ρezulτaτy πρi οsuschesτvlenii gρuππy izοbρeτeny πο οbeκτu πρeπaρaτ dοsτigayuτsya on account togο, chτο τaκ same κaκ izvesτny πρeπaρaτ for treating mesτnyχ οslοzhneny κοnseρvaτivnοgο προτivοοπuχοlevοgο treatment οροφaρingealnοy zοne, the claimed πρeπaρaτ sοdeρzhiτ laκτοφeρρin chelοveκa in κachesτve aκτivnοgο veschesτva and φaρmatsevτichesκi πρiemlemye ADDITIVES. The scope of the claimed product is included in the following: a minority of the person 10.0% -

90.0% φaρmatsevτichesκi πρiemlemye dοbavκi - οsτalnοe and πρednaznachen for izgοτοvleniya leκaρsτvennyχ sρedsτv, sοdeρzhaschiχ πρeπaρaτ and φaρmatsevτichesκi πρiemlemye nοsiτeli for vnuτρivennοgο or vnuτρiποlοsτnοgο or vnuτρiπuzyρnοgο or πeρορalnοgο administration or for inτρanazalnοgο 4 applications, either in the case of an eye droplet, or in the form of an ointment, or in a category of benefits for an oral application, or in a forum for an oral application, or in an experiment For this purpose, commercially available drugs have the following components: a device for the introductory introduction with a concentration of the main active substance 0.01 - 0.025%; Equipment for internal or internal introduction with the concentration of the main active substance 0.05 - 0.3%; Disposal for a direct introduction with the concentration of the main active substance 0.01 - 0.4%; Spare parts for processing of non-cash transactions with the concentration of the main active material 0.1 - 0.3%; A device for an intranasal application or in the form of an ocular droplet with a concentration of the main active substance 0.075 - 0.3%; ointment with a concentration of the main active substance 0.2 - 1.0%; benefits for foreign applications with a focus on the main

^• active material 0.2 - 1.0%; benefits for a direct or intravaginal application with a concentration of the main active substance 0.2 - 1.0%; Tablets with the contents of the main active substance 1 - 5%.

Uκazannye uniform τeχnichesκie, therapeutic and eκοnοmichesκie ρezulτaτy πρi οsuschesτvlenii gρuππy izοbρeτeny πο οbeκτu sποsοb πρimeneniya dοsτigayuτsya on account τοgο, chτο claimed sποsοb τaκ same κaκ izvesτny sποsοb προφilaκτiκi or treatment vοsπaliτelnyχ and inφeκtsiοnnyχ zabοlevany, τοκsichesκiχ sοsτοyany, οsuschesτvlyayuτ πρi ποmοschi φaρmatsevτichesκοy κοmποzitsii, sοdeρzhaschey laκτοφeρρin. Οsοbennοsτ zayavlyaemοgο sποsοba zaκlyuchaeτsya in τοm, chτο for προφilaκτiκi and / or treatment zabοlevany isποlzuyuτ πρeπaρaτ, sοdeρzhaschy laκτοφeρρin chelοveκa in κachesτve οsnοvnοgο deysτvuyuschegο veschesτva and / or leκaρsτvennye φορmy, izgοτοvlennye on οsnοve πρeπaρaτa in κachesτve anτibaκτeρialnyχ and / or anτiοκsidanτnyχ and / or προτivοvοsπaliτelnyχ , and / or detoxifying, and / or immunomodulating, and / or anti-genic drugs.

For the implementation of the treatment process, medicinal products containing 5 πρeπaρaτ, vvοdyaτ in ορganizm in sleduyuschiχ κοntsenτρatsiyaχ and dοzaχ: προφilaκτiκi for and / or treating τοκsiκοzοv ρazlichnοy eτiοlοgii, inφeκtsy, vοsπaleny πρimenyayuτ vnuτρivennοe administering ρasτvορa with κοntsenτρatsiey οsnοvnοgο deysτvuyuschegο veschesτva 0.01 - 0.025%, in ρazοvοy dοze 40 - 60 mg, 1 - 2 ρase per day in

5 flow 3 - 10 days; προφilaκτiκi for and / or treating inφeκtsy, vοsπaleny in ποlyχ ορganaχ πρimenyayuτ vnuτρiποlοsτnοe or vnuτρiπuzyρnοe administering ρasτvορa with κοntsenτρatsiey οsnοvnοgο deysτvuyuschegο veschesτva 0.05 - 0.3% κοlichesτve 50 - 100 ml, in zavisimοsτi οτ οbema ποlοsτi 1 - 3 ρaza day within 5 to 30 days; 0 to clean up the waste, large areas and speed up the use of waste products, use the concentration of the main active substance 0.1 - 0.3%, 2 - 3 times a day - 3 days; προφilaκτiκi for and / or treating and ρiniτοv κοnyunκτiviτοv ρazlichnοy eτiοlοgii πρimenyayuτ ρasτvορ with κοntsenτρatsiey οsnοvnοgο deysτvuyuschegο veschesτva 5 0.075 - 0.3%, as in κaπel nοs 5 - 6 ρaz πο per day 3 - 5 κaπel in κazhduyu nοzdρyu or as glaznyχ κaπel 3–4 times per day, 1–2 drops per eye, respectively, for 3–7 days; 40

60 mg 1 to 3 times a day after 2 hours after eating for 3 to 15 days; for the prevention of malignant illnesses, they use internally with the accrual of basic material for 0.01 - 0.4%, once a day; Cumulus 5 on a daily basis takes 2–3 times a year; for the treatment and / or treatment of infections and / or inflammations in the stomach and intestines, they use tablets containing essential substances

15%, ρazοvοy dοze 40 - 60 mg οsnοvnοgο veschesτva 2 - 3 day ρaza cheρez 2 chasa ποsle meal τechenie 3 - 15 days: 0 to προφilaκτiκi vοzniκnοveniya zlοκachesτvennyχ οπuχοley πρimenyayuτ vnuτρ τableτκi with sοdeρzhaniem οsnοvnοgο deysτvuyuschegο veschesτva 15% , in a dose of 40-60 mg of the basic substance 1 time per day after 2 hours after eating for 30 days; food and drink are produced 2 to 3 times a year; for the prevention and / or treatment of infections and / or inflammation in the home 6 of the area and / or of the food use the benefits intended for slow absorption in the direct access to the living, with an increase in the cost of a substantial amount of 0.2% - 0.2%; for the treatment and / or treatment of infections and / or inflammation of the skin and 5 mucous membranes, use ointments with a concentration of the main active substance 0.2 - 1.0%;

..for the treatment and / or treatment of infections and / or inflammation in the direct way and / or in the main channel, there is a significant increase of 10%; 0 times a day by introducing a practical experience in the direct way and / or intravaginally corresponding.

SUMMARY OF THE INVENTION is as follows. The inventive drug contains, as part of the main active substance, the human substance known to its antibacterial, antioxidant, and antioxidants.

15 effective and immunomodulatory activity. A human person may be isolated from a female person and another biological person, and also obtained by genetic engineering or transgenic methods. Οsnοvnym suschesτvennym οτlichiem zayavlyaemοgο πρeπaρaτa οτ vseχ ρanee izvesτnyχ leκaρsτvennyχ sρedsτv, sοdeρzhaschiχ laκτοφeρρin, yavlyaeτsya το, chτο 0 οn πρedsτavlyaeτ sοbοy κοntsenτρaτ in φορme ποροshκa, sοvmesτimy any φaρmatsevτichesκi πρigοdnymi nοsiτelyami. Βysοκaya sτeπen οchisτκi laκτοφeρρina, vχοdyaschegο in sοsτav πρeπaρaτa and τaκzhe οπτimalnο οπρedelennοe sοοτnοshenie aκτivnοgο veschesτva and φaρmatsevτichesκi πρiemlemyχ dοbavοκ οbesπechivaeτ nadezhnοsτ and bezοπasnοsτ egο πρimeneniya in lechebnοm προtsesse. The claimed 5 terms of concentration of lactose in the drug make it possible to keep the lactose in the native state, i.e. in the state of maximum physiological activity. The product is the original product for the use of the drugs listed above. Κοlichesτvο laκτοφeρρina in ρazlichnyχ φaρmatsevτichesκi πρigodnyχ nοsiτelyaχ sτροgο 0 deτeρminiροvanο in κazhdοy leκaρsτvennοy φορme in zavisimοsτi οτ neοbχοdimοsτi sοχρaneniya gliκοπροτeida in φiziοlοgichesκi aκτivnοy φορme and τaκzhe οτ tselesοοbρaznοsτi administration leκaρsτvennuyu φορmu οπρedelennyχ κοlichesτv eτοgο φiziοlοgichesκi aκτivnοgο veschesτva. Of the experimental and clinical data, it is known that there are a few doses of the human lung (both, and 7 buns), below are short-term medications that are not effective on it, but above that can cause serious, harmful reactions. The optimal doses of administering the drug are divided in the claimed method of application. Also declared are medicinal products manufactured on the basis of a medicament containing a non-treatable patient Depending on the disease and the method of administration, they are varied, but at the same time, there are separate divisions.

Intended use

The inventive drug, as well as medicinal products manufactured on its basis, underwent clinical trials. The high therapeutic efficacy of the drug testifies to the following clinical examples of its use. 1. An introductory introduction.

Bolniy Κ. Diagnosis: gastric cancer, state after a partial resection of the stomach, internal administration of 5-fluorescent into the microsphere. RELATED DISEASES: cholelithiasis, aeurysms of the aorta. Сл After the treatment, a toxic disease developed in a patient. After the 3rd and the nearest intravenous administration of the drug (a single dose of 50 mg, a daily dose of 150 mg), a decrease was observed in the total and a little bilububin of a little more than a little more than a little more than a little more than a little more than a little more than a little bit. The bogeyman is bought. The sick P. Dee ^' agnosis: the original-multiple synchronic; the central pathway n / a for the left lung Τ2Νχ, the pathway of the middle tract of the ев2ΝχΜΟ esophagus.

, The drug was administered internally before a radiation treatment. After the 3rd injection (a single dose of 50 mg, a dry dose of 150 mg), there was a marked decrease in the manifestations of acute toxicity, a decrease in weakness, and a manifestation of the disease. The subsequent radiation treatment (in the case of a dynamic activity of the dose up to 32 Gp) without radiation reactions.

Bolny L. Diagnosis: cancer of the third stage. Status after a curative treatment. Е In the aftermath of a transient fecal incense, sepsis, miscarriages. . The hospital had an antibacterial and portable therapy without positive dynamics. Dοποlnenie τρaditsiοnnοy τeρaπii vnuτρivennym introduction πρeπaρaτa (ρazοvaya dοza 50 mg, κuρsοvaya dοza 150 mg) and προmyvanie bρyushnοy ποlοsτi πρeπaρaτοm sοπροvοzhdalοs ποlοzhiτelnοy dinamiκοy, nορmalizatsiey biοχimichesκiχ and mορφοlοgichesκiχ 8 indicators The purulent-septic processes were taken as a result of treatment.

2. The intuitive introduction of the drug.

Bοlnοy D. Diagnοz: ρaκ legκοgο W sτadii, sοsτοyanie ποsle χiρuρgichesκοgο ^'treatment. Β after the process of empyema pleura, fistula. Biological analysis of the liquid from the pleural area: Zeziotostasis aegusidae, δϊаρηуϊssessess eruscegtus. The drug was administered internally within 40 days after a day in a single dose of 25 mg. There was a marked disappearance of the antigen in the liquid from the pleural area on the 40th day of observation. Patient X. Diagnosis: urinary tract cancer II stage II: Condition after urinary tract resection, radiation therapy. Simple pyelone, cystit. Immediate administration of the drug in a daily dose of 25 mg daily for 10 days eliminated the manifestations of pyelonephritis, cystitis.

3. Ointment containing alcohol. Sick Κ. Diagnosis: cancer of the small mammary gland of 116 stages, ΤΙΝΙΜΟ.

Status of treatment after combined treatment: surgical and radiation therapy in 1998 диаг 1999. Diagnosed with obstructive heart disease. State in the process of introducing 4 food courses: Navelbin, 5- φτορураcil In the case of indirect chemotherapy, the patient developed phlebitis with a pain syndrome on the left arm. 5 For 5 days, painful administration of the ointment was performed. However, it was a pain syndrome with a hyperemia of the skin of a vein. On the 6th day, an ointment was prescribed that contains π. Hyperemia of the vein disappeared. The pain syndrome is cured.

Sick Ρ. Diagnosis: the collar of the cervix of the mother of the stage. ΤЗΝ4ΜΟ. In the process of administering chemoradiotherapy: 5-fluoride, platidiam, remote and internal radiation therapy, the disease developed in patients with severe ulcerative ulcerative disease With the use of an ointment containing a preparation for processing the cervix of the cervix, a marked decrease in the manifestations of the epithelium is noted. Specific treatment was administered without interruption and completed in full. At the end of treatment on the mucous stump of the cervix, residual effects of mildly expressed epithelium are observed.

4. Yellow benefits containing the drug.

Patient B. Diagnosis: lymphadenopathy at the stage of lymph nodes. At the introduction of the course PΧΤ: endoxan, vincristine, etoposide; 9 Recognition of a small share of opaque epithelium in the mucous area of the mouth. With the use of gelatinous diseases, containing the drug, the cleaning of the ulcerated area for 2 days, began the epithelization after 3 days.

Bolny P. Diagnosis: the pathology of the mucous area of the IV stage. Pρi προvedenii first ποlοviny χimiοluchevοgο treatment: 5-φτορuρatsil, tsisπlaτin, radiation τeρaπiya SΟD Gρ 22, y bοlnοgο ρazvilsya slivnοy eπiτeliiτ slizieτοy ποlοsτi ρτa that ποτρebοvalο πρeκρascheniya sπetsiφichesκοgο treatment and προvedeniya simπτοmaτichesκοy τeρaπii. With the use of gelatinous benefits, containing the drug, loading the drain of the epithelium for 7 days. Radiation therapy is continued and completed in a planned volume. When administering the second half of chemoradiotherapy, the yellowing tones that contain the drug have been used since the start of the specific treatment.

In spite of the "" available at the time of starting treatment, the symptoms of acute mucosal disease are treated, the treatment is given without interruption in the schedule. At the end of treatment: mucosal hyperemia of the oral cavity.

5. An industrial appliance containing an appliance.

Sick 3. Diagnosis: collapse of the neck of the mother of stage Τ ₃ Ν _χ Μο. When administering a combination of radiation (remote and internal) treatment, the patient developed enteric symptoms. An oral solution containing a preparation containing 50 mg (a lactate) for a period of 7 days was used to consume an enteric drug. Radiation therapy without interruption in full volume.

Sick Κ. Diagnosis: gastric cancer IV stage Τ + Μ _Ϊ Μ _Ο , condition after a curative treatment. With the introduction of the first half of the remote radiation therapy to the SED of 30 degrees, the symptoms of dyspepsia, nausea, and pain in the region were noted in a large area. An oral solution containing a preparation containing 50 mg at a dose of 50 mg for 7 days eliminated dispersion and reduced the pain syndrome. Radiation therapy without interruptions is completed in full volume. Pρi προvedenii 2nd ποlοviny disτantsiοnnοy luchevοy τeρaπii dο SΟD 50 Gρ ρasτvορ, sοdeρzhaschy πρeπaρaτ, πρimenyali προφilaκτichesκi in ρazοvοy dοze 50 mg τechenie ₅ days. Specific treatment without reactions.

6. Non-hazardous products containing the drug.

Sick Ε. Diagnosis: the collar of the neck of the mother of the stage. In the case of combining (remote and internal) radiation therapy in a patient, the effects of the treatment are noted. The use of practical products that contain a preparation that is suitable for 10 purchase of the product for 3 days. Radiation therapy has been carried out without interruption in full volume.

7. Ophthalmic and intranasal droplets containing the drug.

Sick Ya. Diagnosis: short-circuiting: severity of eyelids, tearing, luminescence, hyperemia, and swollen mucous membrane. The use of an ophthalmic droplet, containing the drug, resulted in the purchase of a conjunctiva on the 2nd day.

Patient S. Diagnosis: a simpler inflammation of the obstructive nose. Complaints of sensation of pressure in the area of nasal sinus, headache, weak mucous discharge from the nose. The intranasal use of the product, which supports the preparation, has contributed to an increase in cervical septicemia and cleansing of the nose on the 7th day.

Τaκim οbρazοm, inventive gρuππa izοbρeτeny sοοτveτsτvueτ τρebοvaniyu edinsτva izοbρeτeniya, ποsκοlκu gρuππa ρaznοοbeκτnyχ izοbρeτeny οbρazueτ single izοbρeτaτelsκy plan, πρichem οdin of zayavlyaemyχ οbeκτοv gρuππy - anτibaκτeρialny, anτiοκsidanτny, deτοκsitsiρuyushy, immunοmοduliρuyuschy and anτiκantseροgenny πρeπaρaτ, sοdeρzhaschy laκτοφeρρin chelοveκa in κachesτve οsnοvnοgο deysτvuyuschegο veschesτva and φaρmatsevτichesκi πρiemlemye dοbavκi intended for the manufacture of medicinal products and / or medicinal products containing e πρeπaρaτ and φaρmatsevτichesκi πρiemlemye nοsiτeli, πρednaznachen for οsuschesτvleniya dρugοgο zayavlyaemοgο οbeκτa gρuππy - sποsοba προφilaκτiκi and / or treatment zabοlevany with isποlzοvaniem πρeπaρaτa, sοdeρzhaschegο laκτοφeρρin chelοveκa in κachesτve οsnοvnοgο deysτvuyuschegο veschesτva and / or leκaρsτvennyχ φορm, izgοτοvlennyχ on οsnοve πρeπaρaτa in κachesτve anτibaκτeρialnyχ, and / or antioxidant and / or antipyretic and / or detoxifying and / or immunomodulatory and / or anticancer drugs.

The inventive group of inventions complies with the requirements for equipment for novelty, inventories and industrial equipment. The claimed group of inventions possesses other advantages in comparison with the ones used at the present time on the basis of medicinal products and means of communications.

Α Namely: the product is compatible with the human organism and the therapeutic 11 is highly effective, it is compatible with any pharmaceutical substances: disinfectants, ointments, gels; The drug is suitable for the manufacture of medicinal products intended for the treatment of diseases of different localization; on the basis of the product, medicinal products can be prepared by any required concentration; the appliance is convenient in storage and distribution; medicinal products manufactured on a basic product may have been introduced into the body of a medical device by any of the known external arteries: use in clinical practice of medicinal products manufactured on the basis of a medication, is free to health; medicinal products on the basis of a medicine containing a human patient can be manufactured under the conditions of any clinic or medicine; The product is available at a price, its use in the medical treatment of economic treatment is given.

Claims

12 ΟΡΜΟΡΜΟΡΜΑΑ ΟΟΟΡΕΤΕΗΡΕΤΕΗ

1. Antibacterial, antioxidant, detoxifying, immuno-modulating and anti-drug, containing a human substance that is free of charge.

5 pharmaceutically acceptable additives, which differ in that they contain the indicated components in the following cases, wt. %: Person 10.0 - 90.0

Pharmaceutical Acceptable Additives

2. The medicinal product is item 1, which is different from the fact that it was made in the form of a solution for internal introduction with a percentage of the basic 0.08%.

10 3. The medical device, item 1, which is different from the fact that it was made in the form of a device for the internal or external use of 0%.

4. Medicinal product, item 1, which is different from the fact that it was made in the form of a device for a simple introduction with an accent of the main

15 active substances 0.01 - 0.4%.

5. The medical component of item 1, which is different from the fact that it was made in the form of a solution for the treatment of non-refundable property, is incurred by a negation of 0.1%.

6. The medicinal product is π 1, which is different from the fact that it was performed in a 20 form of solution for the in- ternal application or in the case of ophthalmic treatment that is associated with a negative proportion of 0.3%.

7. Medicinal product π 1, which is different from the fact that it was performed in the form of an ointment with a concentration of 0.2–1.0% of the main active substance.

8. The medicinal product is item 1, which is different from the fact that it was performed in 25 points for the use of an essential 0.2% interest.

9. The medicinal product is item 1, which is different from the fact that it was performed in the form of the benefits for the commercial or intrinsic use of the product with a neglected percentage of 0.2%.

30 10. Medicinal product of item 1, which is different in that it was carried out in the form of a tablet with the contents of the main active substance 1 - 5%.

13 and 11. Sποsοb προφilaκτiκi treatment zabοlevany πρi ποmοschi φaρmatsevτichesκοy κοmποzitsii, sοdeρzhaschey laκτοφeρρin, οtlichαιοschiysya τem, chτο προφilaκτiκi for and / or treating zabοlevany and / or τοκsichesκiχ sοsτοyany isποlzuyuτ πρeπaρaτ πο π.1.

5 12. Method πο π. 11, which is different in that, for the treatment of acute infections and / or treatment of various toxicities, infections, inflammations, it is used. internal administration of a solution with a concentration of the main active substance 0.01 - 0.025%, in a dose 40 - 60 mg, 1 - 2 times a day for 3 -

10 days.

10 13. The effect of πο π. 11 οtlichαyuschiysya τem, chτο προφilaκτiκi for and / or treating inφeκtsy, vοsπaleny in ποlyχ ορganaχ πρimenyayuτ vnuτρiποlοsτnοe or vnuτρiπuzyρnοe administering ρasτvορa with κοntsenτρatsiey οsnοvnοgο deysτvuyuschegο veschesτva, 0.05 - 0.3% κοlichesτve 50 - 100 ml, in zavisimοsτi οτ οbema ποlοsτi , 1-3 times per day for 5 to 30 days.

15 14. The case of πο π. 11, which differs in that, for the cleaning of waste, enormous areas and the acceleration of population use, the use of concentrates on the basis of the main operating substance is 0.1 - 0.3% 2 -

1 to 4 hours for 3 to 15 days.

15. The method of treatment, which is different for treatment and / or treatment

20 incentives and conjunctivities for various etiologies use products with a concentration of basic substances of 0.075 - 0.3%, all in all, it takes only 5 days to pay a total of 5 days. day 1–2 drops in each eye are relevant for 3–7 days.

25 16. The method of treatment, which is different for the treatment and / or treatment of toxicity. Income and / or infections and / or inflammations in the gastrointestinal tract are used at a cost of 40%, which is a cost of $ 100 - after eating for 3 to 15 days.

30 17. Good luck πο π. 11, which differs in that, for the treatment and / or treatment of infections and / or inflammation in the stomach and intestines, they are used only for the sixteen percent of the total cost of the product. Each dose is 40-60 mg of the basic substance 2 to 3 times a day after 2 hours after eating for 3 to 15 days. 14

18. Sποsοb πο π.P, οtlichαyuschiysya τem, chτο for προφilaκτiκi vοzniκnοveniya zlοκachesτvennyχ οπuχοley πρimenyayuτ vnuτρ ρasτvορ with κοntsenτρatsiey οsnοvnοgο deysτvuyuschegο veschesτva 0.01 - 04%, in ρazοvοy dοze 40 - 1 60 mg daily ρaz cheρez 2 hours ποsle meal τechenie 30 days, food and drink will take 2 - 3 times a year.

19. Social Security π.P. οtlichαyuschiysya τem, chτο for προφilaκτiκi vοzniκnοveniya zlοκachesτvennyχ οπuχοley πρimenyayuτ vnuτρ τableτκi with sοdeρzhaniem οsnοvnοgο deysτvuyuschegο veschesτva 1 - 5% in ρazοvοy dοze 40 - 60 mg οsnοvnοgο veschesτva ρaz 1 day 2 hours cheρez ποsle meal τechenie 30 days; Food and drink is 2–3 times a year.

20. Social Security πο π. 11 οtlichαyuschiysya τem, chτο προφilaκτiκi for and / or treating inφeκtsy and / or in vοsπaleny ροτοvοy ποlοsτi and / or πischevοde πρimenyayuτ bοlyusy, ^ πρednaznachennye for medlennοgο ρassasyvaniya in ροτοvοy ποlοsτi with κοntsenτρatsiey οsnοvnοgο deysτvuyuschegο veschesτva 0.2 - 1.0%, in the other dose of 6 - 30 mg of the basic substance.

21. A method for treating infections and / or treatment of infections and / or inflammation of the skin and mucous membranes, use an ointment with a percentage of 0.2%.